<DOC>
	<DOCNO>NCT00570232</DOCNO>
	<brief_summary>The purpose study determine whether erlotinib effective control cancer return treatment salvage surgery radiation . This study also determine effect , good and/or bad , drug participant .</brief_summary>
	<brief_title>UAB 0718 - Phase II Trial Assess Target Oral Therapy Adjuvant Chemoprevention High-Risk Head Neck Cancer</brief_title>
	<detailed_description>An investigator-initiated Phase II clinical trial safety tolerability erlotinib adjuvant therapy definitive therapy via salvage surgery head neck cancer patient .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Pathologically confirm diagnosis recurrent second primary squamous cell carcinoma 2 . Recurrence second primary oral cavity , oropharynx , hypopharynx , larynx . Recurrent neck metastasis unknown primary allow 3 . Prior radiation therapy head neck cancer 4 . Disease must consider surgically resectable candidate curative reirradiation 5 . Adequate diagnostic workup 6 . Zubrod Performance Status 02 7 . Life expectancy 12 week 8 . Age 19 , 9 . Adequate laboratory data . 1 . Prior invasive cancer head neck cancer unless disease free minimum 3 year . ( Prior nonmelanomatous skin cancer previous carcinoma situ permissible ) 2 . Patients pregnant lactate 3 . Psychological condition render patient unable understand inform consent 4 . Any situation condition interfere adherence study activity .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Resectable , recurrent head neck cancer</keyword>
</DOC>